PRAX · Praxis Precision Medicines, Inc.
$259.86
-3.69 (-1.40%)
At close · Oct 9
Return incl. dividend (before tax)
Market Cap
$7.26B
Shares
27.92M
Volume · Oct 9
517.23K
Avg daily vol (3M)
410.64K
Price & Indicators
20d MA
50d MA
200d MA
Earnings
Filing
Insider
Congress
Investor day
Close$259.86
Open$266.91
Day$259.00–267.85
52W close$52.34–386.33
Avg vol 30d440K
Short int4.2M · 15.0% float · 7.2d
Short vol24%
Last earningsAug 6, 2026
DataOct 2020–Oct 2026
Filing10-Q · Aug 6
Up next
Next earnings call
Nov 3, 2026
Est · unconfirmed
· in 3 wks
filed Aug 6, 2026
call held Aug 6, 2026
Metrics snapshot
Useful current figures from the complete screener profile.
Revenue (TTM)
$0
Trailing 12 months
Net income (TTM)
−$339.13M
Trailing 12 months
Revenue growth YoY
-100.0%
Year over year
Operating margin
—
Trailing 12 months
P / E (TTM)
—
Trailing earnings
FCF yield
-4.2%
TTM · current market cap
Return on invested capital
—
Trailing 12 months
Net cash
$758.55M
Latest balance sheet
Dividend yield
—
Trailing 12 months
Shares change YoY
+35.7%
Year over year · more shares
Price change (1Y)
+385.4%
Trailing year
Short interest
15.0%
Latest settlement · 7.2 days to cover
AI Brief
Q2 FY26 earnings call · Aug 6, 2026
Q2 FY26
TL;DR. Praxis reported successful mid-cycle reviews for both ulixacaltamide (PDUFA Jan 29, 2027) and relutrigine (PDUFA Dec 27, 2026) with no advisory committee and clean BIMO inspections, while advancing commercial launch infrastructure, but the POWER1 study for vormatrigine missed its primary endpoint and cash burn is increasing ahead of launches.
Bullish
- + Both NDAs completed mid-cycle review with no major concerns and no planned advisory committee
- + FDA BIMO inspections of both NDAs completed with no Form 483
- + EMERALD study in broad DEEs exceeded target enrollment with ~200 patients across >50 etiologies, topline expected Q4 2026
- + Elsunersen received third Breakthrough Therapy Designation based on positive EMBRAVE Part A results
- + Cash position of $1.4 billion extends runway into 2028 to support upcoming launches
Bearish
- − Relutrigine NDA review period extended; new PDUFA date moved to December 27, 2026 due to major amendment
- − Q2 net loss widened to $83.7 million from $71.1 million year-over-year with G&A more than doubling
- − Operating cash burn increased to $78 million from $55 million year-over-year with guidance for higher G&A in second half
From the call
AI-generated from the earnings call and 8-K · may contain errors · not investment advice
Equibles Rating
blended score · not investment adviceOverall
Strong Sell
SellHoldBuy
Technical
Sell
Momentum
Very Weak
Sentiment
Neutral
Fundamentals
Poor
Quant / Vol
Very High
Market backdrop
VIX 14.8 · calm
Equity put/call 0.56
Technical
price trend
50 / 200-day cross
No cross
Price vs 200-day avg
−18%
below
Price vs 50-day avg
−21%
below
RSI (14)
27
oversold
MACD trend
Negative
52-week position
62%
mid-range
Volume (OBV)
Confirms
volume backs price
Momentum
relative strength
1-month return
−22%
trailing
6-month return
−24%
trailing
YTD return
−12%
this year
Relative strength
−34%
vs S&P · 6-mo
Sentiment
smart money
Trend (MA cross)
No cross
50d $330 › 200d $317 — 50d above 200d
Institutional flow
Accumulating
4 of 316 funds reported for Sep 30 · net +116 sh shares
Insider flow
Flat
No net insider activity over 90 days
Short interest
Rising
15.00% of float · ▲ +10.3% MoM · 7.2 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Multi-yr high
316 holders — near 3-yr high, broad support
Squeeze score
71
high risk · 0–100
Fundamentals
Revenue growth
−100%
Y/Y
EPS growth
−32%
Y/Y
Free cash flow
$-249.1M
Quant / Vol
risk profile
Volatility
199%
annualized · 1-yr
Max drawdown
−33%
past year
ATR
5.9%
of price · 14-day
Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Technicals
trend & momentum for long-term holders Sell
50 / 200-day cross
No cross
Neutral
Price vs 200-day avg
−18%
Bearish
Price vs 50-day avg
−21%
Bearish
RSI (14)
27
Neutral
MACD trend
Negative
Bearish
52-week position
62%
Neutral
Volume (OBV)
Confirms
Neutral
Market signals — smart money & positioning
Bullish · 2 of 6
Trend (MA cross)
No cross
50d $330 › 200d $317 — 50d above 200d
Institutional flow
Accumulating
4 of 316 funds reported for Sep 30 · net +116 sh shares
Insider flow
Flat
No net insider activity over 90 days
Short interest
Rising
15.00% of float · ▲ +10.3% MoM · 7.2 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Multi-yr high
316 holders — near 3-yr high, broad support
Price context
position in its 52-week range
Range low $52
Now $260 · 62%
Range high $386
vs 200-day avg -18%
vs 50-day avg -21%
Illustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
Earlier KPI extraction records exist, but do not meet the current evidence-completeness requirements. No current verified series is available. Earlier figures remain withheld until revalidated; this is not evidence that the company reports no KPIs.
Versus peers
Biotechnology — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
PRAX
this stock
Praxis Precision Medicines, Inc.
|
$7.26B | -11.8% | -100.0% | — | 15.0% |
|
VRTX
Vertex Pharmaceuticals Inc / Ma
|
$129.29B | +12.5% | +46.2% | 29.7 | 1.8% |
|
MRNA
Moderna, Inc.
|
$89.83B | +663.0% | +4.3% | — | 7.7% |
|
REGN
Regeneron Pharmaceuticals, Inc.
|
$76.86B | -3.3% | +20.8% | 18.5 | 2.1% |
|
CSLLY
Csl Ltd
|
$61.83B | — | — | — | 0.0% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionOwnership
Short & Settlement
Smart Money
Financials
Filings
Earnings & Events
Performance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| PRAX | -12.1% | -22.3% | -24.1% | -10.8% | -11.8% |
| SPY | +1.2% | +1.9% | +9.9% | +2.1% | +14.2% |
| vs SPY | -13.2% | -24.2% | -34.0% | -12.9% | -26.0% |